ArcelorMittal holds investor day in India
September 25, 2024 05:30 ET
|
ArcelorMittal S.A.
Event highlights India’s position as world’s fastest growing steel market and AM/NS India’s vision to become the benchmark for quality, scale and sustainability in Indian steelmaking 25 September...
Kuntarahoitus laskee liikkeeseen 2 miljardin Norjan kruunun vihreän joukkovelkakirjalainan osana joukkovelkakirjalainaohjelmaa
September 25, 2024 03:00 ET
|
Kuntarahoitus Oyj
Kuntarahoitus OyjPörssitiedote25.9.2024 klo 10.00 Kuntarahoitus laskee liikkeeseen 2 miljardin Norjan kruunun vihreän joukkovelkakirjalainan osana joukkovelkakirjalainaohjelmaa Kuntarahoitus Oyj...
Municipality Finance issues NOK 2 billion green bond under its MTN programme
September 25, 2024 03:00 ET
|
Municipality Finance Plc
Municipality Finance PlcStock exchange release 25 September 2024 at 10:00 am (EEST) Municipality Finance issues NOK 2 billion green bond under its MTN programme Municipality Finance Plc issues NOK 2...
21Shares Announces Fee Reduction for Flagship ETPs, HODLX and BOLD
September 24, 2024 03:00 ET
|
21Shares
ZURICH, 24 September 2024 – 21Shares AG ("21Shares"), one of the world's largest issuers of cryptocurrency exchange traded products (ETPs) and a subsidiary of 21.co, is pleased to announce a...
Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis
September 24, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Allschwil, 24. September 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an...
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
September 24, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...
Santhera gibt Annahme des Zulassungsantrags für AGAMREE® (Vamorolon) bei Duchenne-Muskeldystrophie durch Swissmedic bekannt
September 24, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Schweiz, 24. September 2024 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Schweizerische Heilmittelinstitut Swissmedic das Zulassungsgesuch (marketing authorization...
Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy
September 24, 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing...
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
September 24, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers...
Schweiter Technologies Innovation & Capital Markets Day 2024
September 24, 2024 00:00 ET
|
Schweiter Technologies
Ad hoc-Mitteilung gemäss Art. 53 des Kotierungsreglements der SIX Schweiter Technologies Innovation & Capital Markets Day 2024 Profitable growth with sharpened strategy Sharpened strategic...